coronavirus after an inhaled drug was found to lower hospital patients' risk of developing severe disease by 79 per cent. According to early results of the study, patients who received the drug, known as SNG001, were more than twice as likely to recover from Covid-19 compared to those who received a placebo.The treatment has been developed by the pharmaceutical company Synairgen and the trials were led by academics at Southampton University.Previous studies involving asthmatic patients have shown that the drug is well-tolerated, enhances the lungs’ anti-viral defences and improves lung function during cold or flu infection.The current trial was carried out on a double-blind and placebo-controlled basis.What this means is both the.